<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01132040</url>
  </required_header>
  <id_info>
    <org_study_id>P-620/06</org_study_id>
    <nct_id>NCT01132040</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Primidone Tablets 50 mg of Dr. Reddy's Under Fasting Conditions</brief_title>
  <official_title>An Open Label, Balanced. Randomized, Two-treatment, Two-period, Two-sequence, Single Dose,Crossover, Bioequivalence Study of Primidone 50 mg Tablets of Comparing With That of MysolineÂ® 50 mg Tablets Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the bioavailability of Primidone 50 mg tablets of
      Dr.Reddy's comparing with that of Mysoline@ tablets of Yamanouchi Pharma Technologies Inc, in
      healthy, adult, human subjects under fasting conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, balanced. randomized, two-treatment, two-period, two-sequence, single
      dose,crossover, bioequivalence study of Primidone 50 mg tablets of Dr.Reddy's Laboratories
      Limited, Generics, India comparing with that of Mysoline (containing Primidone 50 mg) tablets
      of Yamanouchi Pharma Technologies Inc, Norman, OK in healthy, adult, human subjects under
      fasting conditions with a washout period of 14 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Primidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mysoline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mysoline Tablets of Yamanouchi Pharma Technologies Inc,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primidone</intervention_name>
    <description>Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited</description>
    <arm_group_label>Primidone</arm_group_label>
    <arm_group_label>Mysoline</arm_group_label>
    <other_name>Mysoline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must fulfill all of the following criteria to be considered for inclusion into
        this study:

          1. Subjects who will provide written informed consent.

          2. Subjects must be healthy, adult, human beings within 18-45 years of age (both
             inclusive)weighing at least 50 kg.

          3. Having a Body Mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as
             weight in Kg/height in m2

          4. Subjects must be of normal health as determined by medical history and physical
             examination performed within 21 days prior to the commencement of the study.

          5. Subjects whose screening laboratory values are within normal limits or considered by
             the physician/investigator to be of no clinical significance.

          6. Availability of the subject for the entire study period and willingness to adhere to
             the protocol requirements as evidenced by written informed consent.

        Exclusion Criteria:

        The subjects will be excluded based on the following criteria during screening and during
        the study

          1. Subjects incapable of understanding the informed consent.

          2. Subjects who have:

               1. Systolic blood pressure less than 90 mm ofHg or more than 140 mm of Hg

               2. Diastolic blood pressure less than 60 mm of Hg or more than 94 mm of Hg. Minor
                  deviations (2-4 mm of Hg) at check-in may be acceptable at the discretion of the
                  physician/investigator.

               3. Pulse rate below 50/min or above 100/min.

          3. History of hypersensitivity or idiosyncratic reaction to study drug or any other
             related drugs.

          4. Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal
             function.

          5. Consumption of grapefruit for the past ten days prior to the dosing day until the
             completion of the study.

          6. Regular smoker who has a habit of smoking more than nine cigarettes per day and has
             difficulty in abstaining from smoking from 48 hours before dosing and during sampling
             period.

          7. Subjects who have taken over the counter or prescribed medications and enzyme
             modifying or any systemic medication for during the last 7 and 30 days respectively
             before dosing.

          8. Subjects who have participated in any other clinical investigation using experimental
             drug/donated blood in past 90 days before the date of start of study.

          9. Subjects with clinically significant abnormalities (such as Laboratory Findings, ECG,
             X-Ray,Drugs of abuse, Alcohol etc.,) and/or with significant diseases (such as HIV,
             Hey, Syphilis,Hepatitis B etc.,).

         10. Female subjects who are pregnant or who are able (women with child bearing potential)
             to become pregnant during the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohanlal shiva prasad sayana</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bioserve Clinical Research Pvt. Ltd., Hyderabad, A.P.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bioserve Clinical Research Pvt. Ltd,</name>
      <address>
        <city>HYD</city>
        <state>Andhra Pradesh</state>
        <zip>500 037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2010</study_first_posted>
  <last_update_submitted>May 26, 2010</last_update_submitted>
  <last_update_submitted_qc>May 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mr. Indu Bhushan / Sr. Director - R&amp;D</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Crossover</keyword>
  <keyword>Primidone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

